Janux Therapeutics earnings were -$77.7M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest JANX earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$23.5M, up 16.3% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, JANX reported annual earnings of -$69.0M, with 18.4% growth. The next JANX earnings date is Jun 26, 2025.
What were Janux Therapeutics's earnings last quarter?
On JANX's earnings call on Invalid Date, Janux Therapeutics (NASDAQ: JANX) reported Q1 2025 earnings per share (EPS) of -$0.38, up 26.67% year over year. Total JANX earnings for the quarter were -$23.51 million. In the same quarter last year, Janux Therapeutics's earnings per share (EPS) was -$0.30.
The next JANX earnings call is Invalid Date. Add JANX to your watchlist to be reminded of Janux Therapeutics's next earnings date.
Is Janux Therapeutics profitable or losing money?
As of the last Janux Therapeutics earnings report, Janux Therapeutics is currently losing money. Janux Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$77.74 million, a 39.84% increase year over year.
What was JANX's earnings growth in the past year?
As of Janux Therapeutics's earnings date in Invalid Date, Janux Therapeutics's earnings has grown year over year. JANX earnings in the past year totalled -$77.74 million.
What are Janux Therapeutics's earnings expectations?
The current EPS estimate for Janux Therapeutics's earnings report in Invalid Date is -$0.39.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.